[1]姜炬芳,李天牧,邓五一,等.托瑞米芬与来曲唑在老年乳腺癌术后内分泌治疗中的疗效比较[J].医学临床研究,2016,33(4):722-724,727. [2] 李佳,邓爱民.钙、维生素D及磷代谢在骨质疏松症发病及治疗方面的作用[J].实用医学杂志,2015,31(22):3643-3645. [3] 罗晓辉,刘建舟,门群利,等.唑来膦酸联合内分泌治疗前列腺癌骨转移的临床观察[J].中国现代医学杂志,2015,25(36):90-92. [4] 薛卫成.介绍乳腺癌TNM分期系统(第7版)[J].诊断病理学杂志,2010,17(4):241-244. [5] Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group[J].Osteoporos Int,1994,4(6):368-381. [6] Coleman R, Body JJ, Aapro M,et al. Bone health in cancer patients: ESMO Clinical Practice Guidelines[J].Ann Oncol,2014, 25(3):124-137. [7] Ahlborg HG, Johnell O, Turner CH, et al. Bone loss and bone size after menopause[J].N Engl J Med,2003,349(17):327-34. [8] 熊萍,董刚强,李世云,等.鲑鱼降钙素治疗绝经后骨质疏松症的疗效观察[J].西部医学,2012,24(10):1967-1968. [9] 徐亮,郝晓甍,张敏,等.唑来膦酸预防芳香化酶抑制剂引起骨丢失的临床研究[J].中国肿瘤临床,2010,37(7):392-394. [10] 熊茂强,陈宇,罗展标.唑来膦酸治疗老年男性原发性骨质疏松的临床效果评估[J].医学临床研究,2014,31(5):859-862.
2017, Vol. 34 
